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Clinical trials have evolved from early observational studies into
accepted stages of development culminating in the phase III
randomised clinical trial. The Cochrane collaboration has for many
years sought to promote the quality of clinical trials, and
developed methodology for meta-analysis, to which NICE has
added health economic evaluation to make its cost effectiveness
assessments, the final stage before implementation of research into
clinical practice. It clearly makes sense for the trial population to
reflect as far as possible the wider group in which the therapies will
ultimately be used, and Stead et al (2011) in this issue of the
journal report on 10 years experience of the National Cancer
Research Network in promoting trials in the UK. However, for
many rare tumours that now include subtypes of existing
histopathological categories of cancer defined by molecular
criteria, there are fresh challenges in evaluation of the available
data, and it is noteworthy that the emphasis will change to improve
support in those areas.
The stimulus for change in the UK was a government report in
1999 indicating poor cancer survival figures compared with
Europe, and one of several initiatives was a comprehensive
network of infrastructure support for clinical trials in cancer,
starting in England in 2001 and later extending to the devolved
nations (Scotland, Wales and Northern Ireland). Since 2001 many
EU countries have established national organisations to promote
clinical research, but none to date on the scale of the UK initiative
in providing core infrastructural support for trials. The National
Cancer Research Institute was created as a consortium of
government and charitable funders in the UK, which was linked
to funding of tumour group-specific committees. Representation
was based on trial recruitment as well as geographical spread and
led to the creation of a national portfolio of phase II and III trials.
The traditional model was that industry directly sponsored and
ran registration studies, and provided academic grants to enable
co-operative groups to implement a broader range of supporting
studies across a range of tumour types. In Europe academic
trial funding includes coordinated agencies such as the FP7
programme, as well as individual governments and charities
providing grant support for peer reviewed studies, and co-
operative groups which evolved around individual tumour-related
organisations, in some cases growing to become global in scope.
The EORTC went a stage further by creating additional generic
groups, including some which were at the forefront of translational
research such as receptors, pharmacokinetics and molecular
mechanisms. Most groups operated on the basis of financial
reimbursement per enrolled patient, and the UK model subse-
quently evolved to a hybrid system for more complex trials.
HAS THIS INVESTMENT BEEN SUCCESSFUL?
The answer is a definite yes in some areas, not all of which could
be foreseen at the outset, although in others the jury is still out.
There have been clear overall achievements, and the numbers
speak for themselves with the target of doubling the recruitment to
clinical trials to 7.5% of incident cancer cases met in record time
across the country, and 50% of NHS Trusts achieving a 10% target.
A greater number of patients were recruited than through NCI-
sponsored studies in 2007. Comparisons with the EORTC are less
valid as there are a number of other European organisations
carrying out phase II–III trials. There was also a reduction in the
number of trials failing to meet their target. Perhaps the greatest
achievement, however, was to stimulate a clinical research ethos
across all NHS Trusts in the United Kingdom. Subsequent
developments included the incorporation of research as an integral
part of the work of all NHS hospitals supported by contract-based
funding.
The process was not without its growing pains. The introduction
of Research and Development units in NHS Trusts may have
created ownership and a business model for research, at the
expense of some uniformity and cooperation between individual
organisations, whose varying interpretation of the regulations led
to bureaucratic delays, a process which became a greater problem
after the implementation of the EU clinical trials directive in 2001.
Demand for research nurse time frequently grew to outstrip
availability, particularly for follow-up, and was perhaps a
necessary price of success. A little noticed addition to the
programme in the later years was the incorporation of industry-
sponsored trials, which sowed the seeds for later private public
partnerships. The plethora of targets, compounds and advances in
trial methodology in turn created an environment conducive to
such interaction.
However, the answer to the main question whether overall
cancer survival was improved as a result of the initiative is not
clear. Proving cause and effect is always a challenge for broad
health care interventions, and there are many facets to comparison
of population-based survival assessments from registration criteria
and completeness of data to confounding medical conditions and
social deprivation factors. Even for individual cancers with a clear
aetiological factor such as lung and cervical cancers, or those
which are exquisitely sensitive to treatment such as testicular
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of Health update on the Cancer Reform Strategy published earlier
this year makes no reference to promoting clinical trial activity,
and concentrates on improving earlier diagnosis and uniform
treatment access across the country, without challenging the
historical basis of NHS funding.
SO WHAT OF THE FUTURE?
Tissue sample collection is becoming part of the majority of
clinical trials, which increasingly involve biomarker evaluation as a
secondary or exploratory endpoint. Almost universal in phase I
and II studies, it is now clear that molecular profiling in some
form will be integral to many phase III studies as well. The cost of
next generation sequencing technologies, widely expected to
replace many current biomarkers, is falling at a rate, which will
bring it into the range of a PET scan in the foreseeable future.
Almost half of the NHS cancer networks are associated with
Experimental Cancer Medical Medical Centres (ECMCs), which
concentrate on phase I and II studies, and together with the Cancer
Research Centres bring together expertise from industry and the
Universities.
The improving outcomes strategy also highlights important
programmes such as the Stratified Medicines Innovation Platform
(https://ktn.innovateuk.org/web/stratified-medicines-innovation-
platform), which will provide crucial pilot data on gene sequencing
for six selected tumours. Combined with a funding structure for
quality-controlled molecular diagnostic testing, this would allow
the generation of pre-stratified cohorts of patients for clinical
trials. Upscaling that initiative to a national programme to cover a
broader range of cancers and centres would be a logistical as well
as a financial challenge. However, the achievements of the NCRN
initiative in building cooperation between the government,
national charities and the private sector provide a model from
which to build the vision of personalised cancer medicine
(Gonzalez-Angelo et al, 2010).
The Academy of Medical Sciences report on the EU directive
may lead to more efficient trial approval across the country, with
the creation of the Health Technology Authority (Rawlins, 2011).
Web-based pathology review, and standardisation or centralisation
of molecular analyses will minimise the variation of both inclusion
and assessment criteria, and facilitate international collaboration.
The involvement of industry is important, and may be fostered by
expansion of joint training and exchange of staff. A further mark of
success is that the comprehensive research networks have
extended the model of national clinical research coordination to
areas outside cancer, including diabetes, stroke and mental health.
One gap in the strategy that has received insufficient attention is
communication with patients and their families. Molecular
profiling may lack the instant appeal of a scan, but will characterise
cancers with a much greater sensitivity and increasing specificity.
An informed public will be more likely to participate in research
than a suspicious one, and there is perhaps no better time to spend
a modest proportion of the investment on education of an
increasingly multicultural society on new developments in
biomedical technology.
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